Space
Varda raised $251 million in its Series D funding round.
Publication: Payload
Author: Jacqueline Feldscher
Source published: 30/09/2026, 12:00:00 UTC
Briefing created: 30/09/2026, 12:06:51 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 30/09/2026, 12:05:24 UTC.
Briefings
Varda raised $251M in a Series D round led by Lux Capital and Natural Capital, bringing total capital to nearly $600M. The company, valued at $1.6B, expanded its space pharmaceutical business with new investors including Founders Fund and Khosla Ventures. Varda has flown six re-entry missions since 2023 with over a dozen more planned, including two upcoming launches aboard SpaceX's Transporter-18. Key missions include W-8 for thermal testing and W-9 for hypersonic navigation using Syensqo heat shield tiles. The company aims to leverage zero-gravity conditions for crystallizing pharmaceutical ingredients and testing tech at hypersonic speeds.
Key points
- Varda raised $251M in a Series D round led by Lux Capital and Natural Capital, bringing total capital to nearly $600M.
- The company's W-8 mission launched aboard SpaceX's Transporter-18 to test thermal protection materials on the capsule's exterior.
Context and limitations
Data reflects a single snapshot from September 2026; future mission outcomes and exact re-entry performance metrics remain unverified.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 30/09/2026, 12:06:51 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeiaqyffjluqqqya6vukkmpt3jmhnz3zwr5qn7gc5ty2q3rqy5ezx34